Difference between revisions of "Team:SCU-WestChina/Applied Design"
| Line 105: | Line 105: | ||
<div class="main-wrapper"> | <div class="main-wrapper"> | ||
<div class="primary-wrapper"> | <div class="primary-wrapper"> | ||
| − | <div class="primary-title"> | + | <div class="primary-title">Applied Design</div> |
| − | <div class="primary-content"><br>The | + | <div class="primary-content"><br>1) The clinical treatment by using gut microbes has become a hot research topic in recent years, our project provides a perfect solution for the controversy that whether the hyperuricemia patients without gout symptoms should use drugs with a long-time therapy in a harmless way. There are 100 million of Chinese people are suffering from the risks the disease brings. It is of far-reaching influence to the global prevention of the diseases hyperuricemia cause.</br> |
| + | <br>2)There is no proper treatment for some refractory gout patients all over the world. However, we should not give up on every single patient. Our dialysis device provides an ultimate treatment for those who suffer from refractory gout and are insensitive to Pegloticase. Meanwhile, we have put forward a completely new approach for the treatment of metabolic diseases: with the guidance of synthetic biology and biomedical engineering. It provides a brand new idea for the clinical application of microorganisms.</br> | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 122: | Line 123: | ||
<img src="https://static.igem.org/mediawiki/2017/6/68/T--SCU-WestChina--Wiki-Background-image002.png" alt=""> | <img src="https://static.igem.org/mediawiki/2017/6/68/T--SCU-WestChina--Wiki-Background-image002.png" alt=""> | ||
<div class="img-describe"> | <div class="img-describe"> | ||
| − | Figure 1 Purine catabolism. purine bases are converted, first, into xanthine and, then, into urate for excretion | + | Figure 1 Purine catabolism. purine bases are converted, first, into xanthine and, then, into urate for excretion. |
</div> | </div> | ||
<p> | <p> | ||
| Line 159: | Line 160: | ||
<br></br> | <br></br> | ||
| − | <p>The clinical treatment by using intestinal microbinology has become a hot research topic in recent years. Our intestinal therapy provides a long-time therapy in a harmless way. This project provides a perfect solution for the controversy that whether the hyperuricemia patients without gout symptoms should use drugs. The prevalence rate of hyperuricemia in mainland China has reached 8.4% | + | <p>The clinical treatment by using intestinal microbinology has become a hot research topic in recent years. Our intestinal therapy provides a long-time therapy in a harmless way. This project provides a perfect solution for the controversy that whether the hyperuricemia patients without gout symptoms should use drugs. The prevalence rate of hyperuricemia in mainland China has reached 8.4%, which means that 100 million of Chinese people are suffering from the risks the disease brings. The engineered bacteria constructed in our project provide a new treatment for the hyperuricemia patients all around the world to avoid the use of medications and also help the gout patients to reduce their blood urate concentration. It is of far-reaching influence to the global prevention of gout and the metabolic diseases hyperuricemia cause.</p> |
<br></br> | <br></br> | ||
Revision as of 01:52, 1 November 2017
1) The clinical treatment by using gut microbes has become a hot research topic in recent years, our project provides a perfect solution for the controversy that whether the hyperuricemia patients without gout symptoms should use drugs with a long-time therapy in a harmless way. There are 100 million of Chinese people are suffering from the risks the disease brings. It is of far-reaching influence to the global prevention of the diseases hyperuricemia cause.
2)There is no proper treatment for some refractory gout patients all over the world. However, we should not give up on every single patient. Our dialysis device provides an ultimate treatment for those who suffer from refractory gout and are insensitive to Pegloticase. Meanwhile, we have put forward a completely new approach for the treatment of metabolic diseases: with the guidance of synthetic biology and biomedical engineering. It provides a brand new idea for the clinical application of microorganisms.
Uric acid is a product of purine nucleotide catabolism in nucleic acid constituent units. Most mammals and poultries are able to produce uricase, which decomposes uric acid into allantoin, then into NH3, CO2 and H2O. However, humans and apes lack the ability to produce uricase, so in humans uric acid is the end product of purine metabolism. For humans, increased production or decreased excretion of uric acid can lead to its accumulation in the body, causing hyperuricemia. Research shows that hyperuricemia is an independent risk factor of arteriosclerosis, hypertension, heart failure and metabolic syndrome.
As the concentration of uric acid in blood increases, if sodium urate crystals deposit from super-saturated extracellular fluids to joints, synovium or other tissues and organs, it will cause a syndrome clinically known as "gout", including features like arthritis, tophi, uric acid kidney stones and gouty nephropathy. At this stage the patient suffer from acute gouty arthritis, having acute pains in the joint from time to time.
Controversy still exists on whether to use medications on ordinary patients with hyperuricemia: specialists of rheumatic and immunologic fields state that hyperuricemia without symptoms of gout does not require drug treatment; however, in the Cardiology field hyperuricemia is considered as an independent risk factor of atherosclerosis and need to be controlled by medications. And for patients with refractory gout, traditional drug treatment is slow, taking several years to complete, and for some of them the uric acid level still cannot get low enough for tophi to dissolve. At the same time, for some patients, age factors and complications like hypertension, renal insufficiency, diabetes and vascular disease have also limited drug use on them.
Based on the information above, we speculated that the reduction of intestinal uric acid concentration can mean a reduced serum uric acid concentration, thus treating hyperuricemia. Meanwhile, the use of probiotics offers a perfect solution for the dispute about whether to use medications to treat hyperuricemia: the blood uric acid level is lowered through proper application of intestinal microbes without the administration medications.
We constructed a metabolic pathway of uric acid in E. coli Nissle 1917 expressing urate permease (transporter) on its surface. We try to introduce engineered bacteria into the intestine to consume intestinal uric acid, thus reducing blood uric acid concentration, so as to treat gout.
The clinical treatment by using intestinal microbinology has become a hot research topic in recent years. Our intestinal therapy provides a long-time therapy in a harmless way. This project provides a perfect solution for the controversy that whether the hyperuricemia patients without gout symptoms should use drugs. The prevalence rate of hyperuricemia in mainland China has reached 8.4%, which means that 100 million of Chinese people are suffering from the risks the disease brings. The engineered bacteria constructed in our project provide a new treatment for the hyperuricemia patients all around the world to avoid the use of medications and also help the gout patients to reduce their blood urate concentration. It is of far-reaching influence to the global prevention of gout and the metabolic diseases hyperuricemia cause.
